178 related articles for article (PubMed ID: 34680324)
1. Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma.
Wang Z; Peng Z; Liu Q; Guo Z; Menatola M; Su J; Li T; Ge Q; Wang P; Shen L; Jin R
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680324
[TBL] [Abstract][Full Text] [Related]
2. Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers.
Takeuchi H; Konnai S; Maekawa N; Minato E; Ichikawa Y; Kobayashi A; Okagawa T; Murata S; Ohashi K
Front Vet Sci; 2020; 7():330. PubMed ID: 32596272
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
5. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.
Li X; Chen L; Gu C; Sun Q; Li J
PeerJ; 2020; 8():e9536. PubMed ID: 32874775
[TBL] [Abstract][Full Text] [Related]
6. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
8. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
9. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
10. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
Koh YW; Han JH; Haam S; Jung J; Lee HW
Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074
[TBL] [Abstract][Full Text] [Related]
11. Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.
Xiao M; Hasmim M; Lequeux A; Moer KV; Tan TZ; Gilles C; Hollier BG; Thiery JP; Berchem G; Janji B; Noman MZ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803139
[TBL] [Abstract][Full Text] [Related]
12. The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer.
Li B; Wu S; Qiu Z; Zhong X; Chen Z; Luo F; Li J; Liu K
Neoplasma; 2022 May; 69(3):691-699. PubMed ID: 35293763
[TBL] [Abstract][Full Text] [Related]
13. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
[TBL] [Abstract][Full Text] [Related]
14. CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma.
Gao H; Yin J; Guan X; Zhang S; Peng S; Liu X; Xing F
Funct Integr Genomics; 2023 Sep; 23(4):306. PubMed ID: 37726578
[TBL] [Abstract][Full Text] [Related]
15. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
[TBL] [Abstract][Full Text] [Related]
16. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
[TBL] [Abstract][Full Text] [Related]
17. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
18. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
19. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
20. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T; Yu H; Dai X; Zhang X
Front Immunol; 2022; 13():971428. PubMed ID: 35958549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
